Key Highlights

  • Theriva Biologics (NYSEAMERICAN:TOVX) reported cash of USD 11.3 million at June 30, 2026 against a screen Market Value of USD 8.44 million.
  • 22nd Century Group (NASDAQ:XXII) shareholders approved on August 5, 2026 a reverse split of up to 1-for-200 aimed at Nasdaq listing requirements.
  • Acumen Pharmaceuticals (NASDAQ:ABOS) shows USD 0.24, up 14.09%, on 33.72 million shares (relative Volume 4.42) and a market value of USD 17.34 million on the penny stocks screen, as of the capture on November 4, 2026.
  • Hain Celestial (NASDAQ:HAIN) shows USD 0.13, up 12.59%, on 2.72 million shares (relative volume 1.35) and a market value of USD 12.20 million on the penny stocks screen, as of the capture on November 4, 2026.

1. Theriva Biologics (NYSEAMERICAN:TOVX)

On the penny stocks screen, Theriva Biologics (NYSEAMERICAN:TOVX) appears at USD 0.18, up 7.92%, on 91.36 million shares (relative volume 168.17, unverified) and a market value of USD 8.44 million, as of the capture on November 4, 2026. A price below USD 1 is not a verdict on a business, but it can bring Listing Rules into play, such as the Nasdaq minimum bid price, and make financing dilutive for TOVX holders. It plans to discuss a Phase 2 and 3 retinoblastoma trial protocol with the FDA in the third quarter of 2026, and enrolment in a trial of SYN-004 is paused pending funding. The USD 8.44 million screen market value is below the June cash figure, simple arithmetic across a screen and a stale date. The screen shows a loss per share of USD 0.67. The risk is that the cash runway ends in the first quarter of 2027, so financing is likely, and a small name can see quoted moves reverse.

2. 22nd Century Group (NASDAQ:XXII)

On the penny stocks screen, 22nd Century Group (NASDAQ:XXII) appears at USD 0.07, up 6.47%, on 214.68 million shares (relative volume 3.16) and a market value of USD 1.42 million, as of the capture on November 4, 2026. For XXII, market value and volume matter more than price: a market value of a few million USD means a small number of trades can set the quote. They ratified 3,019,586 inducement warrants issued in June 2026. Published coverage reported an earlier 1-for-15 reverse split announced in January 2026, a single source item treated as approximate. The screen loss per share of USD 644.21 looks distorted and is not used. This is a small and thinly traded name, so a few trades can move the quote, spreads can be wide and a gain can reverse.

3. Acumen Pharmaceuticals (NASDAQ:ABOS)

Acumen Pharmaceuticals (NASDAQ:ABOS) said on October 30, 2026 that its Phase 2 trial missed its primary endpoint and that it is ending the programme. A price below USD 1 is not a verdict on a business, but it can bring listing rules into play, such as the Nasdaq minimum bid price, and make financing dilutive for ABOS holders. Published coverage of the Quarterly Report put cash, equivalents and marketable securities at USD 78.6 million at the end of September and the quarterly net loss at USD 25.4 million, before the trial result was announced. Published coverage reported a one day fall of about 91% on October 30, a single source figure treated as approximate, which would make the latest rise a bounce from a very low base. The screen market value of USD 17.34 million is below the USD 78.6 million cash figure, simple arithmetic across a screen and a reported number. At this size a small number of trades can move the price, spreads can be wide and quoted moves can reverse, so a gain says nothing about what comes next.

4. Hain Celestial (NASDAQ:HAIN)

Hain Celestial (NASDAQ:HAIN) faces a Nasdaq deadline of March 22, 2027 to lift its shares back to USD 1.00. For HAIN, market value and volume matter more than price: a market value of a few million USD means a small number of trades can set the quote. Published coverage of the Annual Report put Debt of about USD 558 million due December 22, 2026 against about USD 58 million of cash, with Going Concern doubt; these figures are single source and approximate. The screen shows a loss per share of USD 3.36 and a Neutral rating. To regain compliance the shares must close at or above USD 1.00 for at least ten consecutive Business days, and the company says it may use a Reverse Stock Split if needed. The risk is a going concern doubt with debt due on December 22, 2026, and a quote that can move sharply on small trades.

5. Senti Biosciences (NASDAQ:SNTI)

Senti Biosciences (NASDAQ:SNTI) stockholders approved a Merger on October 15, 2026 that pays no cash at closing and offers contingent value rights of up to USD 60.0 million. SNTI is on this list because the penny stocks screen filters for very low share prices, where small orders can move a quote and spreads can be wide. The screen shows a loss per share of USD 1.77. The rights pay USD 10.0 million on a regulatory filing acceptance for SENTI-202, USD 20.0 million on FDA approval and USD 30.0 million if cumulative net sales exceed USD 200.0 million, all within seven years. This is a small and thinly traded name, so a few trades can move the quote, spreads can be wide and a gain can reverse.

Where Things Stand

It means a very small free float where a few trades set the quote. Theriva Biologics (NYSEAMERICAN:TOVX) and ABOS trade below their reported cash figures, XXII is worth USD 1.42 million, and HAIN and SNTI have debt or note events close by, so low prices reflect real financial strain and not just opportunity. The penny stocks screen filters for very low share prices. At these levels a small number of trades can move a quote, spreads can be wide, and listing rules, reverse splits and financing can matter more than operations. A price move says little about what comes next.